Clal Insurance Enterprises Holdings Ltd Sells 300,000 Shares of Cellebrite DI Ltd. $CLBT

Clal Insurance Enterprises Holdings Ltd reduced its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 8.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,173,014 shares of the company’s stock after selling 300,000 shares during the quarter. Clal Insurance Enterprises Holdings Ltd’s holdings in Cellebrite DI were worth $43,724,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Voss Capital LP boosted its stake in shares of Cellebrite DI by 18.9% in the 4th quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock valued at $145,142,000 after purchasing an additional 1,277,300 shares in the last quarter. Pertento Partners LLP grew its stake in shares of Cellebrite DI by 28.2% during the fourth quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock valued at $107,447,000 after buying an additional 1,311,109 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Cellebrite DI by 0.8% in the fourth quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock worth $101,026,000 after buying an additional 43,041 shares during the period. Granahan Investment Management LLC increased its holdings in shares of Cellebrite DI by 16.3% in the fourth quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock worth $55,118,000 after buying an additional 427,719 shares during the period. Finally, Cooper Creek Partners Management LLC bought a new stake in shares of Cellebrite DI in the 3rd quarter valued at about $55,999,000. Institutional investors own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on CLBT. DA Davidson started coverage on Cellebrite DI in a research report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price target on the stock. Needham & Company LLC cut their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Cellebrite DI currently has an average rating of “Moderate Buy” and an average target price of $21.40.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT opened at $14.75 on Wednesday. The stock’s 50-day moving average is $14.10 and its 200 day moving average is $14.36. The company has a market cap of $3.68 billion, a PE ratio of 52.68, a P/E/G ratio of 1.90 and a beta of 1.17. Cellebrite DI Ltd. has a 1 year low of $11.02 and a 1 year high of $19.98.

Insider Transactions at Cellebrite DI

In related news, CRO Marcus Jewell sold 12,658 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the transaction, the executive owned 440,101 shares in the company, valued at $5,620,089.77. This represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David Barter sold 41,734 shares of the firm’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the sale, the chief financial officer directly owned 334,219 shares of the company’s stock, valued at $5,474,507.22. The trade was a 11.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 158,191 shares of company stock worth $2,479,438. 5.70% of the stock is currently owned by insiders.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.